NCT04601974View on ClinicalTrials.gov

Lentiviral Gene Therapy for Epilepsy

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2032

Conditions

Drug Resistant Epilepsy

Interventions

GENETIC

lentiviral gene therapy

lentiviral gene therapy to treat drug resistant epilepsy

Sponsors

Collaborators (1)

Medical Research Council

All Listed Sponsors

collaborator

Medical Research Council

OTHER_GOV

lead

University College, London

OTHER